Efficacy and safety of denosumab from a phase III, randomized, active-controlled study compared with zoledronic acid in patients of Asian ancestry with bone metastases from solid tumors

MLA

Zefei Jiang, et al. “Efficacy and Safety of Denosumab from a Phase III, Randomized, Active-Controlled Study Compared with Zoledronic Acid in Patients of Asian Ancestry with Bone Metastases from Solid Tumors.” Journal of Clinical Oncology, vol. 34, May 2016, p. 10116. EBSCOhost, https://doi.org/10.1200/jco.2016.34.15_suppl.10116.

APA

Zefei Jiang, Yanmei Xu, Jie Dong, Wangjun Liao, Yang Yao, Li Zhang, Shukui Qin, Jianxing He, Ying Cheng, Qingyuan Zhang, & Zhimin Shao. (2016). Efficacy and safety of denosumab from a phase III, randomized, active-controlled study compared with zoledronic acid in patients of Asian ancestry with bone metastases from solid tumors. Journal of Clinical Oncology, 34, 10116. https://doi.org/10.1200/jco.2016.34.15_suppl.10116

Chicago

Zefei Jiang, Yanmei Xu, Jie Dong, Wangjun Liao, Yang Yao, Li Zhang, Shukui Qin, et al. 2016. “Efficacy and Safety of Denosumab from a Phase III, Randomized, Active-Controlled Study Compared with Zoledronic Acid in Patients of Asian Ancestry with Bone Metastases from Solid Tumors.” Journal of Clinical Oncology 34 (May): 10116. doi:10.1200/jco.2016.34.15_suppl.10116.